Basic Information
| LncRNA/CircRNA Name | THOR |
| Synonyms | Lnc-THOR, ENSG00000226856 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | renal cell carcinoma |
| ICD-0-3 | C64.9 |
| Methods | qPCR, Western blot etc. |
| Sample | renal cell carcinoma tissues, cell lines (HK-2, 786-O, A498 and ACH) |
| Expression Pattern | up-regulated |
| Function Description | We show that THOR is expressed in human renal cell carcinoma (RCC) tissues and established/primary human RCC cells. It was not detected in normal renal tissues nor in HK-2 and primary human renal epithelial cells. THOR silencing (by targeted siRNAs) or CRISPR/Cas9 knockout inhibited RCC cell growth, viability and proliferation in vitro. Reversely, forced over-expression of THOR promoted RCC cell survival and proliferation. IGF2BP1-regulated genes, including IGF2, GLI1 and Myc, were downregulated by THOR silencing or knockout, but they were upregulated after THOR over-expression. |
| Pubmed ID | 29752937 |
| Year | 2018 |
| Title | LncRNA THOR promotes human renal cell carcinoma cell growth. |
External Links
| Links for THOR | GenBank HGNC NONCODE |
| Links for renal cell carcinoma | OMIM COSMIC |